EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives

Whi-An Kwon iD, Yong Sang Song iD, Min-Kyung Lee

Cancers · 18.09.2024 · 16 (18) · 3187

DOI: 10.3390/cancers16183187 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.09.2024. Verfasst von Whi-An Kwon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korean government (MSIT), Technology Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The contemporary treatment for metastatic castration-sensitive prostate cancer (mCSPC) has evolved significantly, building on successes in managing metastatic castration-resistant prostate cancer (mCRPC). Although androgen deprivation therapy (ADT) alone has long been the cornerstone of mCSPC treatment, combination therapies have emerged as the new standard of care based on recent advances, offering improved survival outcomes. Landmark phase 3 trials demonstrated that adding chemotherapy (docetaxel) and androgen receptor pathway inhibitors to ADT significantly enhances overall survival, particularly for patients with high-volume, high-risk, or de novo metastatic disease. Despite these advancements, a concerning gap between evidence-based guidelines and real-world practice remains, with many patients not receiving recommended combination therapies. The challenge in optimizing therapy sequences, considering both disease control and treatment burdens, and identifying clinical and biological subgroups that could benefit from personalized treatment strategies persists. The advent of triplet therapy has shown promise in extending survival, but the uro-oncology community must narrow the gap between evidence and practice to deliver the most effective care. Current research is focused on refining treatment approaches and utilizing biomarkers to guide therapy selection, aiming to offer more personalized and adaptive strategies for mCSPC management. Thus, aligning clinical practices with the evolving evidence is urgently needed to improve outcomes for patients facing this incurable disease.

Schlagwörter

Stichwörter der Autor:innen

combination therapydoublet therapymetastatic castrate sensitive prostate cancerprostate cancersystemic treatmenttriplet therapy

Autor:innen und Institutionen

  • Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea.
  • Department of Obstetrics and Gynecology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea.
  • Department of Internal Medicine, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea.

ORCID-Profile: Whi-An Kwon, Yong Sang Song

Förderung

  • National Research Foundation of Korea
  • Korean government (MSIT)
  • Technology Innovation Program
  • Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea

Zitieren

APA

Kwon, W. A., Song, Y. S., & Lee, M. K. (2024). Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives. Cancers, 16(18), 3187. https://doi.org/10.3390/cancers16183187

Vancouver

Kwon WA, Song YS, Lee MK. Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives. Cancers. 2024;16(18):3187. doi:10.3390/cancers16183187

BibTeX
@article{Kwon2024,
  author = {Kwon, Whi-An and Song, Yong Sang and Lee, Min-Kyung},
  title = {Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {18},
  pages = {3187},
  doi = {10.3390/cancers16183187}
}
Kostenlos starten →